Category Archives: Anticipation (35 USC 102)

Injunction, damages, infringement and invalidity decisions regarding Illumina’s fetal testing patents affirmed

Verinata Health, Inc., Illumina, Inc. v. Ariosa Diagnostics, Inc., Roche Mol. Sys., Inc. Docket No. 22018-2198, -2303, -2305, -2306, -2317 REYNA, WALLACH, HUGHES April 24, 2020 (Non-precedential) Brief Summary: DC denial of injunction and damages, as well as its refusal … Continue reading

Posted in Anticipation (35 USC 102), Doctrine of equivalents, Enablement, Infringement, Software | Leave a comment

Prior knowledge or use, public use, and on-sale bar holdings reversed (e.g., must be accessible to the public)

BASF Corp. v. SNF Holding Company, et al. Docket No. 2019-1243 LOURIE, REYNA, HUGHES April 8, 2020 Brief Summary: DC decisions finding prior knowledge or use, public use, and on-sale bar reversed and remanded. Summary: BASF appealed DC decision granted … Continue reading

Posted in Anticipation (35 USC 102), On-Sale Bar, Public Accessibility, Public Use | Leave a comment

Acoustic’s IPR time-bar arguments waived; anticipation and obviousness findings affirmed

Acoustic Technology, Inc. v. Itron Networked Solutions, Inc. Docket No. 2019-1061 (IPR2017-1061) (see also FC Docket Nos. 2019-1059, -1060) MOORE, REYNA, TARANTO February 13, 2020 Brief Summary: Appeal based on time-bar arguments not presented to the Board were waived; anticipation … Continue reading

Posted in Anticipation (35 USC 102), Appeal, Expert Testimony, Inter Parties Review (IPR), IPR, Obviousness | Leave a comment

Board erroneously excluded Apple’s reply arguments as new, not presented in IPR petition

Apple Inc. v. Andrea Electronics Corporation Docket No. 2018-2382, -2383 (IPR2017-00626, -00627) DYK, PLAGER, STOLL February 7, 2020 Brief Summary: Board erroneously excluded Apple’s IPR reply arguments as new as compared to IPR petition (‘626 remanded), and no anticipation or … Continue reading

Posted in Anticipation (35 USC 102), Inter Parties Review (IPR), IPR, Obviousness, Uncategorized | Leave a comment

Board IPR obviousness conclusion affirmed (cannot “ignore the skilled artisan’s knowledge”)

Koninklijke Philips N.V. v. Google, LLC, Microsoft Corp. et al. Docket No. 2019-1177 (IPR2017-00447) MOORE, O’MALLEY, STOLL January 30, 2020 Brief Summary: Board IPR obviousness determination regarding Phillips’s claims affirmed (e.g., § 311(b) limitation on prior art does not mean … Continue reading

Posted in Anticipation (35 USC 102), Inter Parties Review (IPR), IPR, Obviousness, Uncategorized | Leave a comment

Galderma’s ivermectin claims not inherently anticipated since “claimed efficacy limitations” not disclosed by single prior art reference

Galderma Labs., L.P. et al. v. Teva Pharmaceuticals, Inc. Docket No. 2019-2396, -1213 MOORE, O’MALLEY, STOLL January 29, 2020 Non-precedential Brief Summary: DC finding of inherent anticipation reversed as it relied on a second reference to provide limitations missing from … Continue reading

Posted in Anticipation (35 USC 102), Generics / ANDA, Inherency | Leave a comment

Genentech’s antibody purification claims correctly found anticipated or obviousness in IPR, Fed. Cir. decides

Genentech, Inc. v. Hospira, Inc. (United States, Intervenor) Docket Nos. 2018-1933 (IPR2016-01837) PROST, NEWMAN, CHEN January 10, 2020 Brief Summary: Board’s IPR anticipation and obviousness findings affirmed. Summary: Genentech appealed PTAB (“Board”) IPR final written decision (FWD) finding certain claims … Continue reading

Posted in Anticipation (35 USC 102), Inherency, Inter Parties Review (IPR), IPR, Obviousness, Obviousness (Secondary Considerations), Uncategorized | Leave a comment

DC decision of infringement and no Safe Harbor (§ 271(e)(1)) for Hospira’s EPO affirmed

Amgen Inc. et al. v. Hospira, Inc. Docket Nos. 2019-1067, -1102 MOORE, BRYSON, CHEN December 16, 2019 Brief Summary: DC denial of JMOL and new trial after jury findings of infringement, no anticipation and no Safe Harbor for certain batches … Continue reading

Posted in Anticipation (35 USC 102), Claim Construction, Infringement, Safe Harbor, FDA exemptions (271(e)(1)), Uncategorized | Leave a comment

Board PGR obviousness decision vacated for disregarding evidence of copying as irrelevant

Liqwd, Inc. v. L’Oreal USA, Inc. Docket Nos. 2018-2152 (PGR2017-00012) REYNA, HUGHES, STOLL October 30, 2019 Brief Summary: Board PGR obviousness decision vacated for error in disregarding evidence of copying as irrelevant. Summary: Liqwd appealed Board post-grant review (PGR) decision … Continue reading

Posted in Anticipation (35 USC 102), Obviousness, Post-grant review, Uncategorized | Leave a comment

Board decision finding Google did not show anticipation or obviousness affirmed

Google LLC v. Kininklijke Philips, N.V. Docket Nos. 2018-2213 (IPR2017-00437) Moore, Bryson, Chen October 23, 2019 Non-precedential Brief Summary: Board IPR decision that Google did not show the challenged claims to be anticipated or obvious affirmed. Summary: Google appealed Board … Continue reading

Posted in Anticipation (35 USC 102), Inter Parties Review (IPR), IPR, Obviousness, Uncategorized | Leave a comment